MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

A Pilot Study of Optical Molecular Imaging for Percutaneous Biopsy of Hepatocellular Carcinoma Using Indocyanine Green

Early Phase 1

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Biological: ICG
Device: Optical molecular imaging

First Posted Date: 2013-10-14

Last Posted Date: 2018-04-25

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 20

Registration Number: NCT01962649

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Galectin-3 Blockade in Patients With High Blood Pressure

Not Applicable

Completed

Conditions: Hypertension

Interventions: Dietary Supplement: Modified Citrus Pectin (MCP) vs placebo

First Posted Date: 2013-10-11

Last Posted Date: 2021-02-21

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 59

Registration Number: NCT01960946

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Abiraterone Acetate for Castrate Resistant Prostate Cancer

Not Applicable

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone
Drug: Prednisone

First Posted Date: 2013-10-11

Last Posted Date: 2024-05-23

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 40

Registration Number: NCT01961843

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Refractory Acute Myeloid Leukemia
Relapsed Acute Myeloid Leukemia

Interventions: Drug: cabozantinib

First Posted Date: 2013-10-11

Last Posted Date: 2017-07-21

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 18

Registration Number: NCT01961765

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy

Recruiting

Conditions: Prostate Cancer

First Posted Date: 2013-10-11

Last Posted Date: 2024-05-23

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 200

Registration Number: NCT01961713

Locations: 🇺🇸
Massachsuetts General Hospital, Boston, Massachusetts, United States

Comparison of Treatments for Barrett's Esophagus With High-Grade Dysplasia/Early Adenocarcinoma

Not Applicable

Completed

Conditions: Barrett's Esophagus

Interventions: Device: Radio-Frequency Ablation
Device: Cryotherapy

First Posted Date: 2013-10-11

Last Posted Date: 2022-01-12

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 50

Registration Number: NCT01961778

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage

Phase 3

Withdrawn

Conditions: Heart Failure
Pulmonary Hypertension

Interventions: Drug: Placebo
Drug: Tadalafil

First Posted Date: 2013-10-10

Last Posted Date: 2017-09-12

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT01960153

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Real-Time Antiretroviral Therapy Adherence Intervention in Uganda

Not Applicable

Completed

Conditions: HIV/AIDS
Adherence

Interventions: Device: Fixed SMS, real-time monitoring
Device: Triggered SMS, real-time monitoring

First Posted Date: 2013-10-08

Last Posted Date: 2017-05-03

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 63

Registration Number: NCT01957865

Locations: 🇺🇬
Mbarara Immune Suppression Syndrome(ISS) Clinic, Mbarara, Mbarara District, Uganda

Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma

Phase 2

Completed

Conditions: Bile Duct Cancer
Intrahepatic Cholangiocarcinoma
Cholangiocarcinoma of the Extrahepatic Bile Duct

Interventions: Drug: Cabozantinib

First Posted Date: 2013-10-07

Last Posted Date: 2017-02-03

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 19

Registration Number: NCT01954745

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Effect of Video Monitor Size on Adenoma Detection Rate

Not Applicable

Completed

Conditions: Colon Adenoma

Interventions: Device: Monitor size

First Posted Date: 2013-09-30

Last Posted Date: 2017-05-30

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 1805

Registration Number: NCT01952418

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy